Citius Pharmaceuticals (Nasdaq:CTXR) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CTXR 주식 개요

바이오 제약 회사인 씨티어스 제약은 중환자 치료 제품의 개발 및 상용화에 주력하고 있습니다.

CTXR 기본 분석
눈송이 점수
가치 평가	4/6
미래 성장	5/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 98.4% 에서 거래

수익은 매년 69.7% 증가할 것으로 예상됩니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

지난 1년 동안 주주가 희석되었습니다.

의미 있는 시가총액이 없습니다. ( $100M )

최근 3개월간 주가 변동성

Citius Pharmaceuticals, Inc. 경쟁사

Ikena Oncology

NasdaqGM:IKNA

US$82.0m

Aclaris Therapeutics

NasdaqGS:ACRS

US$84.9m

Landos Biopharma

NasdaqCM:LABP

US$71.7m

Nutriband

NasdaqCM:NTRB

US$66.6m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Citius Pharmaceuticals
과거 주가
현재 주가	US$0.43
52주 최고치	US$1.07
52주 최저치	US$0.43
베타	1.61
11개월 변경	-18.11%
3개월 변경 사항	-27.89%
1년 변경 사항	-35.41%
33년 변화	-78.73%
5년 변화	-28.86%
IPO 이후 변화	-97.11%

최근 뉴스 및 업데이트

Recent updates

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Apr 06

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Dec 08

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Aug 01

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Apr 12

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Jul 12

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Sep 26

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28

Citius: Halt For Superiority On The Horizon

Jun 15

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

May 15

Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results

Apr 26

Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Dec 18

주주 수익률

	CTXR	US Pharmaceuticals	US 마켓
7D	-16.8%	-0.09%	0.4%
1Y	-35.4%	19.0%	32.6%

수익률 대 산업: CTXR 지난 1년 동안 15.5 %를 반환한 US Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: CTXR 지난 1년 동안 24.7 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is CTXR's price volatile compared to industry and market?
CTXR volatility
CTXR Average Weekly Movement	13.4%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

안정적인 주가: CTXR 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: CTXR 의 주간 변동성( 14% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2007	22	Leonard Mazur	citiuspharma.com

바이오 제약 회사인 씨티어스 파마슈티컬스는 중환자 치료 제품의 개발과 상용화에 주력하고 있습니다. FDA 승인을 받은 제품인 림피어는 피부 T세포 림프종 치료의 초기 적응증에 대한 표적 면역 요법입니다. 후기 단계 파이프라인에는 카테터 관련 혈류 감염 환자의 카테터 구출을 위한 항생제 잠금 솔루션인 미노록과 치질 완화를 위한 국소 제제인 CITI-002(헤일로-리도)가 포함됩니다.

Citius Pharmaceuticals, Inc. 기본 사항 요약

Citius Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
CTXR 기본 통계
시가총액	US$78.43m
수익(TTM)	-US$39.77m
수익(TTM)	n/a

0.0x

P/S 비율

-2.0x

P/E 비율

CTXR 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
CTXR 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$39.77m
수익	-US$39.77m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.22
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

CTXR 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

CTXR 주식 개요

보상

위험 분석

Citius Pharmaceuticals, Inc. 경쟁사

NasdaqGM:IKNA

US$82.0m

NasdaqGS:ACRS

US$84.9m

NasdaqCM:LABP

US$71.7m

NasdaqCM:NTRB

US$66.6m

가격 내역 및 성능

최근 뉴스 및 업데이트

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Price target increased by 22% to US$4.67

Forecast breakeven date pushed back to 2026

Recent updates

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Price target increased by 22% to US$4.67

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

New major risk - Financial position

New minor risk - Profitability

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

New minor risk - Share price stability

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Price target decreased by 21% to US$3.17

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Consensus EPS estimates fall by 24%

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Forecast breakeven date pushed back to 2025

Price target increased by 25% to US$5.00

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Price target decreased to US$3.60

Insufficient new directors

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals GAAP EPS of -$0.06

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Price target increased to US$4.00

Insufficient new directors

Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. Announces Executive Changes

Critical Care Biopharma - Citius Pharmaceuticals

Forecast breakeven date pushed back to 2024

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777)

Citius: 2022 Is A Year Of Catalysts

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Forecast breakeven date moved forward to 2023

Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma